BLB&B Advisors LLC lifted its holdings in shares of AstraZeneca plc (NYSE:AZN) by 133.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 54,849 shares of the company’s stock after purchasing an additional 31,388 shares during the period. BLB&B Advisors LLC’s holdings in AstraZeneca were worth $1,903,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of AZN. Russell Investments Group Ltd. lifted its holdings in shares of AstraZeneca by 198.9% during the third quarter. Russell Investments Group Ltd. now owns 1,856,140 shares of the company’s stock worth $62,883,000 after purchasing an additional 1,235,239 shares during the period. Sector Gamma AS acquired a new position in shares of AstraZeneca during the third quarter worth $25,094,000. Janus Henderson Group PLC lifted its holdings in shares of AstraZeneca by 5,754.0% during the third quarter. Janus Henderson Group PLC now owns 726,599 shares of the company’s stock worth $24,617,000 after purchasing an additional 714,187 shares during the period. Voya Investment Management LLC lifted its holdings in shares of AstraZeneca by 38.2% during the second quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock worth $81,661,000 after purchasing an additional 662,481 shares during the period. Finally, Point72 Asset Management L.P. lifted its holdings in shares of AstraZeneca by 103.1% during the third quarter. Point72 Asset Management L.P. now owns 1,224,939 shares of the company’s stock worth $41,501,000 after purchasing an additional 621,831 shares during the period. Institutional investors own 14.75% of the company’s stock.
AstraZeneca plc (NYSE AZN) traded down $0.47 during trading hours on Tuesday, hitting $35.18. 2,477,318 shares of the stock traded hands, compared to its average volume of 3,225,278. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $89,050.00, a P/E ratio of 25.13, a PEG ratio of 3.42 and a beta of 0.76. AstraZeneca plc has a one year low of $26.51 and a one year high of $35.92.
AstraZeneca (NYSE:AZN) last posted its earnings results on Thursday, November 9th. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.57 by $0.55. The company had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.32 earnings per share. equities research analysts predict that AstraZeneca plc will post 1.88 earnings per share for the current year.
Several equities analysts recently issued reports on AZN shares. Sanford C. Bernstein upgraded shares of AstraZeneca from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $30.00 to $39.00 in a report on Friday, September 22nd. BNP Paribas upgraded shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a report on Monday, September 25th. Credit Suisse Group upgraded shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a report on Monday, October 16th. Cowen restated a “hold” rating and issued a $37.00 target price on shares of AstraZeneca in a report on Tuesday, October 17th. Finally, Citigroup upgraded shares of AstraZeneca to a “buy” rating in a report on Wednesday, October 18th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $34.20.
TRADEMARK VIOLATION NOTICE: “BLB&B Advisors LLC Acquires 31,388 Shares of AstraZeneca plc (AZN)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/16/blbb-advisors-llc-acquires-31388-shares-of-astrazeneca-plc-azn.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.